N,N-diethyl-2-fluoroisonicotinamide | 1176209-97-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: N,N-diethyl-2-fluoroisonicotinamide
• 英文别名: N,N-diethyl-2-fluoropyridine-4-carboxamide
• CAS: 1176209-97-4
• 化学式: C₁₀H₁₃FN₂O
• 分子量: 196.224
• InChiKey: HVYXMPYXRUYGEB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  33.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N,N-diethyl-2-fluoroisonicotinamide 在 正丁基锂 、 硼烷 、 盐酸羟胺 、 potassium acetate 、 溶剂黄146 、 二异丙胺 、 锌 作用下， 以 四氢呋喃 、 甲醇 、 正己烷 、 水 为溶剂， 反应 35.08h， 生成 N,N-diethyl-N-[(3-aminomethyl-2-fluoropyridin-4-yl)methyl]amine
  参考文献：
  名称：

  Single Photon Emission Computed Tomography/Positron Emission Tomography Imaging and Targeted Radionuclide Therapy of Melanoma: New Multimodal Fluorinated and Iodinated Radiotracers

  摘要：

  This study reports a series of 14 new iodinated and fluorinated compounds offering both early imaging (I-123, I-124, F-18) and systemic treatment (I-131) of melanoma potentialities. The biodistribution of each I-125-labeled tracer was evaluated in a model of melanoma B16F0 bearing mice, using in vivo serial gamma scintigraphic imaging. Among this series, [I-125]56 emerged as the most promising compound in terms of specific tumoral uptake and in vivo kinetic profile. To validate our multimodality concept, the radiosynthesis of [F-18]56 was then optimized and this radiotracer has been successfully investigated for in vivo PET imaging of melanoma in B16F0- and B16F10-bearing mouse model. The therapeutic efficacy of [I-131]56 was then evaluated in mice bearing subcutaneous B16F0 melanoma, and a significant slow down in tumoral growth was demonstrated. These data support further development of 56 for PET imaging (F-18, I-124) and targeted radionuclide therapy (I-131) of melanoma using a single chemical structure.

  DOI：

  10.1021/jm101574q
• 作为产物：
  描述：

  N,N-二乙基异烟酰胺 在 silver(II) fluoride 作用下， 以 乙腈 为溶剂， 反应 1.0h， 以66%的产率得到N,N-diethyl-2-fluoroisonicotinamide
  参考文献：
  名称：

  受经典胺化反应启发的吡啶和二嗪的选择性 CH 氟化

  摘要：

  氟化吡啶 将氟取代基附加到碳中心通常用于调节药物和农业化学研究中的小分子特性。然而，氟化通常需要使用腐蚀性、危险的试剂。Fier 和 Hartwig (p. 956) 提出了一种异常温和且方便的方案，用于氟化吡啶和相关含氮芳烃中与氮相邻的碳位点。该反应需要用二氟化银处理并在室温下快速进行。温和的氟化方法可以帮助生产医学研究中感兴趣的化合物。氟化杂环广泛存在于药物、农用化学品和材料中。然而，将氟结合到杂芳烃中的反应范围有限并且可能是危险的。我们提出了一种广泛适用且安全的方法，用于使用市售的氟化银 (II) 对吡啶和二嗪中的单个碳氢键进行位点选择性氟化。反应在环境温度下在 1 小时内发生，并且对氮附近的氟化具有唯一的选择性。温和的条件允许获得具有重要医学意义的化合物的氟化衍生物，以及通过随后的氟化物亲核置换制备的一系列 2-取代吡啶。机理研究表明，经典的吡啶胺化途径可适用于广泛范围的氮杂环的选择性氟化。反应在环境温度下在

  DOI：

  10.1126/science.1243759

文献信息

• LABELLED ANALOGUES OF HALOBENZAMIDES AS MULTIMODAL RADIOPHARMACEUTICALS AND THEIR PRECURSORS
  申请人：Chezal Jean-Michel

  公开号：US20110044899A1

  公开（公告）日：2011-02-24

  A compound of formula (I): in which R 1 represents a hydrogen atom, an optionally labelled halogen, a radionuclide or a Sn[(C 1 -C 4 )alkyl] 3 group, Ar represents an aryl group or a heteroaryl group, R 9 represents a hydrogen atom, a (C 1 -C 4 ) alkyl group or forms together with the group R 1 —Ar a ring fused with the Ar group, A represents a group of formula (β) or (δ): R 3 and R 4 independently represent a hydrogen atom, a (C 1 -C 6 )alkyl group, a (C 1 -C 6 ) alkenyl group or a group of formula (y): wherein R 11 represents an optionally labelled halogen, a radionuclide, an aryl or heteroaryl group optionally substituted by an optionally labelled halogen, a radionuclide, a —NO 2 group, a —NR 5 R 6 group, a N + R 5 R 6 R 7 X − group, or a —OSO 2 R 12 group, and their addition salts with pharmaceutically acceptable acids.

  化合物的化学式为(I)：其中R1代表氢原子、可选择标记的卤素、放射性核素或Sn[(C1-C4)烷基]3基团，Ar代表芳基或杂芳基，R9代表氢原子、(C1-C4)烷基或与基团R1-Ar共同形成与Ar基团融合的环，A代表化学式(β)或(δ)的基团：R3和R4分别独立地代表氢原子、(C1-C6)烷基、(C1-C6)烯基或化学式(y)的基团：其中R11代表可选择标记的卤素、放射性核素、可选择取代的芳基或杂芳基，取代基可以是可选择标记的卤素、放射性核素、—NO2基团、—NR5R6基团、N+R5R6R7X−基团或—OSO2R12基团，以及它们与药物可接受的酸形成的加合物。
• C-H FLUORINATION OF HETEROCYCLES WITH SILVER (II) FLUORIDE
  申请人：THR REGENTS OF THE UNIVERSITY OF CALIFORNIA

  公开号：US20160185723A1

  公开（公告）日：2016-06-30

  The present invention provides compositions and methods for the selective C—H fluorination of nitrogen-containing heteroarenes with AgF 2 , which has previously been considered too reactive for practical, selective C—H fluorination. Fluorinated heteroarenes are prevalent in numerous pharmaceuticals, agrochemicals and materials. However, the reactions used to introduce fluorine into these molecules require pre-functionalized substrates or the use of F 2 gas. The present invention provides a mild and general method for the C—H fluorination of nitrogen-containing heteroarene compounds to 2-fluoro-heteroarenes with commercially available AgF 2 . In various embodiments, these reactions occur at ambient temperature within one hour and occur with exclusive selectivity for fluorination at the 2-position. Exemplary reaction conditions are effective for fluorinating diazine heteroarenes to form a single fluorinated isomer.

  本发明提供了使用AgF2对含氮杂环进行选择性C-H氟化的组合物和方法，这在以前被认为过于反应活泼而不适用于实际的选择性C-H氟化。氟代杂环在许多药物、农药和材料中广泛存在。然而，用于将氟引入这些分子的反应需要预功能化的底物或使用F2气体。本发明提供了一种轻柔且通用的方法，用于使用商业上可获得的AgF2对含氮杂环化合物进行C-H氟化，以形成2-氟杂环。在各种实施例中，这些反应在一个小时内在室温下发生，并且仅在2位进行氟化的选择性非常高。示例反应条件对于氟化二氮杂环以形成单个氟代异构体是有效的。
• Labelled analogues of halobenzamides as multimodal radiopharmaceuticals and their precursors
  申请人：INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

  公开号：US09125937B2

  公开（公告）日：2015-09-08

  The present invention relates to the compound of formula (I): in which R1 represents a hydrogen atom, an optionally labelled halogen, a radionuclide or a Sn[(C1-C4)alkyl]3 group, Ar represents an aryl group or a heteroaryl group, R9 represents a hydrogen atom, a (C1-C4)alkyl group or forms together with the group R1—Ar a ring fused with the Ar group, A represents a group of formula (β) or (δ): R3 and R4 independently represent a hydrogen atom, a (C1-C6)alkyl group, a (C1-C6)alkenyl group or a group of formula (γ): —Y—Z—W—R11  (γ) wherein R11 represents an optionally labelled halogen, a radionuclide, an aryl or heteroaryl group optionally substituted by an optionally labelled halogen, a radionuclide, a —NO2 group, a —NR5R6 group, a —N+R5R6R7X− group, or a —OSO2R12 group, and their addition salts with pharmaceutically acceptable acids. The present invention also relates to pharmaceutical compositions comprising them and to their use in diagnosis, in particular with SPECT or PET imaging and in therapy of melanoma via targeted radionuclide therapy.

  本发明涉及公式（I）的化合物： 其中，R1代表氢原子，可选择标记的卤素，放射性核素或Sn[(C1-C4)烷基]3基团； Ar代表芳基或杂芳基； R9代表氢原子，(C1-C4)烷基或与基团R1-Ar一起形成与Ar基团融合的环； A代表公式（β）或（δ）的基团： R3和R4独立地代表氢原子，(C1-C6)烷基，(C1-C6)烯基或公式（γ）的基团： -Y-Z-W-R11（γ） 其中，R11代表可选择标记的卤素，放射性核素，芳基或杂芳基，可选择地被可选择标记的卤素，放射性核素，-NO2基团，-NR5R6基团，-N+R5R6R7X-基团或-OSO2R12基团取代； 以及与药学上可接受的酸形成的加成盐。 本发明还涉及包含它们的制药组合物以及它们在诊断中的应用，特别是在SPECT或PET成像中以及通过靶向放射性核素治疗黑色素瘤的治疗中的应用。
• US9125937B2
  申请人：——

  公开号：US9125937B2

  公开（公告）日：2015-09-08
• US9701635B2
  申请人：——

  公开号：US9701635B2

  公开（公告）日：2017-07-11